A Phase 2 interventional study of ORMD-0801 Treatment A and ORMD-0801 Treatment B in Type 1 Diabetes, sponsored by Oramed, Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-02.
Sponsored by Oramed, Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing insulin in Diabetes Mellitus, Type 1 — 4 open to participants now, 4 under way, none of them phase 3. Insulin · Diabetes Mellitus, Type 1.
Among the 51 studies testing insulin in Diabetes Mellitus, Type 1, this one is the 21st largest by enrollment, is one of 4 that started in 2019, is one of 16 in phase 2, and was the 44th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →4 of the 51 studies testing insulin in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:
Sam Chun Dang Pharm. Co. Ltd. · Sites in Germany
Ages 18–64 · Men only
Ohio State University · Sites in United States
Ages 18+ · Women only
Emory University · Sites in United States
Ages 18+
University of Campania Luigi Vanvitelli · Sites in Italy
Ages 18–30
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 8 · Phase 4 10
First in 1994; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 20 across the 51 interventional studies. Of the 41 that completed or were terminated, 15 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 51 have an industry lead sponsor. The 10 most frequent:
Oramed, Ltd. is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Oramed, Ltd. has 2 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
3 of the studies testing insulin in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03463564University of Campania Luigi VanvitelliInsulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients | 2026-12 |
| NCT06699810Emory UniversityModeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity | 2027-01 |
| NCT07293715Ohio State UniversityPermissive Versus Strict Intrapartum Glucose Management in Type 1 and Type 2 Diabetes (PRISM) | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 51 studies testing insulin in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a Phase 2 randomized, crossover study comparing ORMD-0801 given QD versus TID in subjects with T1D. Subjects with T1D will have a screening visit (Visit 1) during which they will be required to review and sign the informed consent form. Medical history and demographics will be collected. Vital signs will be measured, physical exam will be performed, and blood and urine samples will be collected for hematology/chemistry/urinalysis
Placebo capsules will be given QD at bedtime during placebo run-in period 10 days prior to randomization.
This study is a Phase 2 randomized, crossover study comparing ORMD-0801 given QD versus TID in subjects with T1D. Subjects with T1D will have a screening visit (Visit 1) during which they will be required to review and sign the informed consent form. Medical history and demographics will be collected. Vital signs will be measured, physical exam will be performed, and blood and urine samples will be collected for hematology/chemistry/urinalysis. Eligible subjects will be scheduled to return to the clinic in 1 week (Visit 2). Subjects fulfilling all inclusion/exclusion criteria will have a CGM placed, provided with a diary, dispensed Placebo capsules and asked to return to the clinic in 10 Days (Visit 3, Day 1) for randomization. At Visit 3, data from CGM will be downloaded and diaries will be collected. Blood samples will be collected in fasting for chemistry and HbA1c. Subjects will be randomized to receive either ORMD-0801 24 mg given once daily at bedtime, or ORMD-0801 8 mg given three times a day, 45-90 minutes before meals.
Subjects will be instructed to continue their normal diet, and to adjust their basal and bolus insulin in the normal fashion. Subjects will be instructed to return to the clinic 10 days before Visit 5 (Visit 4, Day 18). At Visit 4, compliance will be assessed, IMP and diary dispensed and the CGM will be placed. Subjects will be instructed to return to the clinic in 10 days for Visit 5 (Day 28). At Visit 5 a fasting blood sample for chemistry panel and HbA1C will be drawn and after the diary has been collected and the CGM monitor removed, they will be crossed over to the alternate treatment regimen. IMP will be dispensed, and the subject will be asked to return 10 days before Visit 7 for Visit 6 (Day 46). At Visit 6, compliance will be checked, IMP and diary will be dispensed and the CGM will be placed. Subjects will be instructed to return in 10 days for Visit 7 (Day 56). At Visit 7 the CGM will be removed, compliance checked, the diary will be collected, and a blood sample will be drawn for a chemistry panel and HbA1C. A physical examination will be performed, and the subject will exit the study. Subjects will be provided with diaries at Visits 2, 4 and 6, and will be asked to capture the amount of basal and bolus exogenous insulin administered each day and calculate their carbohydrate count for all meals and snacks over the 10-day CGM monitoring period. Diaries will be collected at Visits 3, 5 and 7.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
T1D subjects must have:
Females who are not of childbearing potential are defined as:
Subjects who are of childbearing potential must:
a. agree to remain abstinent from heterosexual activity† or agree to use (or have their partner use) acceptable to prevent pregnancy within the projected duration of the trial and for 14 days after the last dose of blinded product. Two methods of contraception will be used to avoid pregnancy. Acceptable combinations of methods include: i. Use of one of the following double-barrier methods: diaphragm with spermicide and a condom; cervical cap and a condom; or a contraceptive sponge and condom ii. Use of hormonal contraception (any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent [including oral, subcutaneous, intrauterine and intramuscular agents, and cutaneous patch]) with one of the following: diaphragm with spermicide; cervical cap; contraceptive sponge; condom; vasectomy; or IUD. iii. Use of an IUD with one of the following: condom; diaphragm with spermicide; contraceptive sponge; vasectomy; or hormonal contraception (see above).
iv. Vasectomy with one of the following: diaphragm with spermicide; cervical cap; contraceptive sponge; condom; IUD; or hormonal contraception (see above).
†Abstinence can be used as the sole method of contraception if it is in line with the subject's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.
Exclusion Criteria:
Use of the following medications:
Laboratory abnormalities at Screening including:
Any abnormality at Screening or cardiovascular disease. Clinically significant cardiovascular disease will include:
a. History of stroke, , or myocardial infarction within 6 months prior to Screening,
Presence or history of cancer within the past 5 years of Screening, with the exception of adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment administered in the following order: 1. Period 1: Placebo (Fish Oil Capsule) 2. Period 2: Treatment A: 24 mg ORMD-0801;(16 mg + 8 mg capsules) Once Daily (QD) at Bedtime 3. Period 3:Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals
Drug: ORMD-0801 Treatment A · Drug: ORMD-0801 Treatment B · Other: Placebo
Treatment administered in the following order: 1. Period 1: Placebo (Fish Oil Capsule) 2. Period 2:Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals 3. Period 3: Treatment A: 24 mg ORMD-0801;(16 mg + 8 mg capsules) Once Daily (QD) at Bedtime Treatment B: 8 mg ORMD-0801; one 8 mg capsule three times a day (TID) 45-90 minutes before meals
Drug: ORMD-0801 Treatment A · Drug: ORMD-0801 Treatment B · Other: Placebo
Treatment A: 24 mg (16 mg capsule + 8 mg capsule) Once Daily (QD) at bedtime
Also known as: Oral Insulin
Treatment B: 8 mg (8 mg capsule) three times a day (TID) 45-90 minutes before meals
Also known as: Oral Insulin
Fish oil capsule
Average Exogenous Basal Insulin Compared to Baseline (Placebo)
The least squares means difference of basal exogenous insulin between treatment A and placebo and treatment B and placebo, utilized over the final ten (10) days of each treatment period
Time frame: Combined Final ten days of each treatment period. Period1 (days -8 to 1)Period 2 (days 19 to 28) ,and Period 3 (days 47 to 56)
Average Exogenous Bolus Insulin Compared to Baseline (Placebo)
The amount of exogenous bolus insulin utilized over the final ten (10) days of each treatment period measured in mg/dL
Time frame: Combined Final ten days of treatment per treatment period (Days -8 to 1, Days 19 to 28, and Days 47 to 56)
Average Exogenous Total Insulin Compared to Baseline
The Least Squares Mean Difeerence ( (mg/dL) of total exogenous insulin (the sum of basal + bolus exogenous insulin) over the final ten (10) days of treatment.
Time frame: Combined Final ten days of treatment , day -8 to 1 (Period 1) Days 19 to 28 (Period 2), Days 47 to 56 (Period 3)
Daytime Average Mean Glucose Compared to Baseline
Least Squares Mean Difference from Baseline of Daytime Average Mean Glucose over the final ten (10) days of each treatment and each treatment period as measured by CGM.
Time frame: Combined Study days -8 to 1 (Period 1) Days 19 to 28 (Period 2), and days 47 to 56 (Period 3)
Daytime Glucose Coefficient of Variation Compared to Baseline
Least Squares Mean Continuous Glucose Monitor (CGM) Glucose Coefficient of Variation measured over daytime hours, compared to Baseline
Time frame: Study Days -8 to 1 (Period 1), Days 19-28 (Period 2), and Days 47-56 (Period 3)
Daytime Low Blood Glucose Index (LBGI) Compared to Baseline
Least Squares Mean Daytime Low Blood Glucose Index (LBGI) measured over the last ten (10) days of the treatment period, compared to Baseline LBGI is a clinical scale that indicates the probability for hypoglycemia. Blood Glucose Variability is an important measure because it provides additional clarification for HbA1c value. The risk of hypglycemic events and the LBGI scale is defined as follows: Minimal Risk ( LBGI \< 1.1) Low Risk ( 1.1 \< LBGI \< 2.5) Moderate Risk (2.5 \< LBGI \< 5), HIgh Risk ( LBGI \> 5)
Time frame: Combined Study Days -8 to 1 (Period 1), Days 19-28 (Period 2), and Days 47-56 (Period 3)
| Milestone | Placebo Followed by Treatment A Followed by Treatment B | Placebo Followed by Treatment B Followed by Treatment A |
|---|---|---|
| Started | 14 | 16 |
| Completed | 14 | 16 |
| Not completed | 0 | 0 |
| Milestone | Placebo Followed by Treatment A Followed by Treatment B | Placebo Followed by Treatment B Followed by Treatment A |
|---|---|---|
| Started | 14 | 16 |
| Completed | 14 | 16 |
| Not completed | 0 | 0 |
| Milestone | Placebo Followed by Treatment A Followed by Treatment B | Placebo Followed by Treatment B Followed by Treatment A |
|---|---|---|
| Started | 14 | 16 |
| Completed | 12 | 15 |
| Not completed | 2 | 1 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Patient non-compliance | 0 | 1 |
The least squares means difference of basal exogenous insulin between treatment A and placebo and treatment B and placebo, utilized over the final ten (10) days of each treatment period
| mg/dL | Baseline | Treatment A | Treatment B |
|---|---|---|---|
| Least Squares Mean Baseline, Treatment A, Treatment B | 27.28 ± 2.489 | 25.84 ± 2.486 | 27.32 ± 2.492 |
| Least Squares Mean Difference Treatment A minus Baseline or Treatment B minus Baseline | NA ± NA | -1.43 ± 0.381 | 0.04 ± 0.421 |
The amount of exogenous bolus insulin utilized over the final ten (10) days of each treatment period measured in mg/dL
| mg/dL | Baseline | Treatment A | Treatment B |
|---|---|---|---|
| Least Squares Means Baseline, Treatment A, Treatment B | 20.63 ± 2.033 | 20.77 ± 2.045 | 20.54 ± 2.049 |
| Least Squares Means Difference Treatment A minus Baseline, Treatmen B minus Baseline | NA ± NA | 0.14 ± 0.634 | -0.09 ± 0.645 |
The Least Squares Mean Difeerence ( (mg/dL) of total exogenous insulin (the sum of basal + bolus exogenous insulin) over the final ten (10) days of treatment.
| mg/dL | Baseline | Treatment A | Treatment B |
|---|---|---|---|
| Least Squares Mean | 47.92 ± 3.395 | 46.64 ± 3.397 | 47.88 ± 3.406 |
| Least Squares Mean Difference Treatment A minus Baseline and Treatment B minus Baseline | NA ± NA | -0.127 ± 0.758 | -0.04 ± 0.798 |
Least Squares Mean Difference from Baseline of Daytime Average Mean Glucose over the final ten (10) days of each treatment and each treatment period as measured by CGM.
| mg/dL | Baseline | Treatment A | Treatment B |
|---|---|---|---|
| Least Sqaures Mean Baseline, Treatment A, Treatment B | 168.72 ± 5.825 | 174.84 ± 5.957 | 169.75 ± 5.930 |
| Least Squares Mean Difference between each treatment and placebo | NA ± NA | 6.12 ± 3.966 | 1.02 ± 3.889 |
Least Squares Mean Continuous Glucose Monitor (CGM) Glucose Coefficient of Variation measured over daytime hours, compared to Baseline
| percent (%) | Baseline | Treatment A | Treatment B |
|---|---|---|---|
| Least Squares Mean | 45.287 ± 2.3191 | 46.550 ± 2.3073 | 44.996 ± 2.2847 |
| Least Squares Mean Differece between each treatment and placebo. | NA ± NA | 1.64 ± 1.949 | -0.291 ± 1.9064 |
Least Squares Mean Daytime Low Blood Glucose Index (LBGI) measured over the last ten (10) days of the treatment period, compared to Baseline LBGI is a clinical scale that indicates the probability for hypoglycemia. Blood Glucose Variability is an important measure because it provides additional clarification for HbA1c value. The risk of hypglycemic events and the LBGI scale is defined as follows: Minimal Risk ( LBGI \< 1.1) Low Risk ( 1.1 \< LBGI \< 2.5) Moderate Risk (2.5 \< LBGI \< 5), HIgh Risk ( LBGI \> 5)
| units on a scale | Baseline | Treatment A | Treatment B |
|---|---|---|---|
| Least Squares Mean Daytime Low Blood Glucose Index (LBGI) for Baseline, | 1.65 ± 0.284 | 1.53 ± 0.282 | 1.65 ± 0.288 |
| Least Squares Mean Difference between Treatment A and Placebo, Treatment B and Placebo. | NA ± NA | -0.12 ± 0.294 | 0.00 ± 0.297 |
Collected over Sixty-six (66) days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Treatment A ORMD-0801 | 0/30 (0%) | 0/30 (0%) | 9/30 (30%) |
| Treatment B ORMD-0801 | 0/30 (0%) | 0/30 (0%) | 6/30 (20%) |
| Event | Placebo | Treatment A ORMD-0801 | Treatment B ORMD-0801 |
|---|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 0/30 | 2/30 | 0/30 |
| DiarrhoeaGastrointestinal disorders | 0/30 | 2/30 | 0/30 |
| NasopharangitisInfections and infestations | 0/30 | 0/30 | 1/30 |
| OTITIS EXTERNAInfections and infestations | 0/30 | 0/30 | 1/30 |
| SinusitisImmune system disorders | 0/30 | 0/30 | 1/30 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/30 | 1/30 | 1/30 |
| Urinary Tract InfectionInfections and infestations | 0/30 | 1/30 | 1/30 |
| HypoglycemiaMetabolism and nutrition disorders | 0/30 | 1/30 | 0/30 |
| HypoglycemiaMetabolism and nutrition disorders | 0/30 | 1/30 | 1/30 |
| Abdominal discomfortGastrointestinal disorders | 0/30 | 1/30 | 0/30 |
All patients are first administered a placebo, or is the standard of care.
| Age, Continuous(years) | Placebo Followed by Treatment A Followed by Treatment B | Placebo Followed by Treatment B Followed by Treatment A | Total |
|---|---|---|---|
| Mean | 43.79285714 ± 12.67793142 | 42.88125 ± 16.04131614 | 43.30667 ± 12.22325 |
| Sex: Female, Male(Participants) | Placebo Followed by Treatment A Followed by Treatment B | Placebo Followed by Treatment B Followed by Treatment A | Total |
|---|---|---|---|
| Female | 7 | 8 | 15 |
| Male | 7 | 8 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Followed by Treatment A Followed by Treatment B | Placebo Followed by Treatment B Followed by Treatment A | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 13 | 15 | 28 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo Followed by Treatment A Followed by Treatment B | Placebo Followed by Treatment B Followed by Treatment A | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 14 | 14 | 28 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Pre-dose Hb1Ac(%)(percent) | Placebo Followed by Treatment A Followed by Treatment B | Placebo Followed by Treatment B Followed by Treatment A | Total |
|---|---|---|---|
| Mean | 7.735714286 ± 0.734435569 | 7.6125 ± 0.848429922 | 7.67 ± 0.786 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Feb 2020, 3 months.
Results were first posted in Jun 2022, 2 years 3 months after primary completion.
Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 3 months is below that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin
Oramed, Ltd.